Prospective Head-to-Head Comparison of Fibroblast Imaging with [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT and [<sup>18</sup>F]FDG PET/CT in Unclear Hepatic Lesions.
Where this comes from
- Record sourced from PubMed, PMID 41991336.
- Also identified by DOI 10.2967/jnumed.125.271597.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed to compare the performance of <sup>68</sup>Ga-labeled fibroblast activation protein inhibitor 46 ([<sup>68</sup>Ga]Ga-FAPI-46) PET/CT and [<sup>18</sup>F]FDG PET/CT in characterizing unclear hepatic lesions. <b>Methods:</b> We prospectively evaluated 59 patients with suspected intrahepatic lesions. Tumor radiologic features, pathology, or follow-up examinations were assessed as reference methods in correlation with PET scans. On [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT, additional abdominal dynamic imaging was performed. We measured the SUV and calculated tumor-to-liver background ratios for both scans. Fibroblast activation protein expression was assessed by immunohistochemistry in samples obtained from 16 patients with hepatocellular carcinoma/cholangiocarcinoma, intrahepatic metastases (IMs) from extrahepatic malignancies, or benign lesions. <b>Results:</b> Primary hepatobiliary tumors (PHBTs), including 76 hepatocellular carcinomas in 22 patients, 24 cholangiocarcinomas in 5 patients, 136 IMs in 16 patients, and 55 benign lesions in 16 patients, were determined by histology (<i>n</i> = 162) and radiologic examinations (<i>n</i> = 129). On the basis of visual analysis, 44 patients showed elevated [<sup>68</sup>Ga]Ga-FAPI-46 uptake (sensitivity, 100%; specificity, 94%), whereas 32 patients showed [<sup>18</sup>F]FDG-avid lesions (sensitivity, 70%; specificity, 88%). Sensitivity was significantly higher in [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT than in [<sup>18</sup>F]FDG PET/CT (<i>P</i> < 0.001). Fifty (90.9%) benign liver lesions in 14 patients (87.5%) showed negligible uptake on both PET scans, and 1 (1.8%) benign liver lesion in 1 patient showed increased [<sup>18</sup>F]FDG uptake alone. [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT revealed 10 extrahepatic primary tumors, versus 3 in [<sup>18</sup>F]FDG PET/CT. SUV<sub>max</sub> for PHBTs, maximum tumor-to-background ratio for PHBTs, and mean tumor-to-background ratio for PHBTs were significantly higher on [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT than on [<sup>18</sup>F]FDG PET/CT (all <i>P</i> < 0.05). <b>Conclusion:</b> [<sup>68</sup>Ga]Ga-FAPI-46 PET/CT is superior to [<sup>18</sup>F]FDG PET/CT in characterizing unclear hepatic lesions.
Medical subject headings
- Fluorodeoxyglucose F18
- Positron Emission Tomography Computed Tomography
- Liver Neoplasms
- Fibroblasts